Document 0259
 DOCN  M95A0259
 TI    Effect of lithium in immunodeficiency: improved blood cell formation in
       mice with decreased hematopoiesis as the result of LP-BM5 MuLV
       infection.
 DT    9510
 AU    Gallicchio VS; Hughes NK; Tse KF; Ling J; Birch NJ; Hematology/Oncology
       Division Chandler Medical Center, University; of Kentucky, L.P. Markey
       Cancer Center, Lexington 40536-0084,; USA.
 SO    Antiviral Res. 1995 Mar;26(2):189-202. Unique Identifier : AIDSLINE
       MED/95328861
 AB    Lithium salts have been demonstrated to induce the production of
       hematopoietic cells following administration in vivo and to minimize the
       reduction of these cells following treatment with either radiation,
       chemotherapeutic or antiviral drugs. We have previously demonstrated
       that lithium, when administered in vivo to immunodeficient mice infected
       with LP-BM5 MuLV (MAIDS) significantly reduced the development of
       lymphadenopathy, splenomegaly, and the lymphoma associated with
       late-stage immunodeficiency disease in this model, and increased the
       survival of these animals compared to virus-infected controls not
       receiving lithium. We report here the results of in vivo studies in the
       MAIDS model that determined the effect of lithium on peripheral blood
       indices and the number of myeloid (CFU-GM), erythroid (BFU-E) and
       megakaryocyte (CFU-Meg) hematopoietic progenitors from bone marrow and
       spleen harvested from immunodeficient mice receiving lithium carbonate
       (1 mM) placed in their drinking water compared to virus-infected
       controls not receiving lithium. Time-points evaluated were at weeks 1,
       5, 9, 13, 17, and 21 postviral infection. Virus-control mice not
       receiving lithium demonstrated all the signs that are characteristic of
       MAIDS, i.e., splenomegaly, lymphadenopathy, hypergammaglobulinemia,
       reduced hematopoiesis, and death. Infected mice receiving lithium
       demonstrated diminished presence of splenomegaly, lymphadenopathy,
       hypergammaglobulinemia, no suppression of hematopoiesis nor mortality.
       Enhanced hematopoiesis was demonstrated by neutrophilia, lymphocytosis,
       thrombocytosis, and erythrocytosis that was evident by increased
       myeloid, erythroid, and megakaryocyte progenitor cells cultured from
       bone marrow and spleen. These studies further demonstrate that lithium
       influences the disease process in the MAIDS model and restricts the
       development of hematopoietic suppression that develops in this
       retroviral animal model of immunodeficiency.
 DE    Animal  Female  Hematopoiesis/*DRUG EFFECTS  Hematopoietic Stem
       Cells/DRUG EFFECTS  Lithium/*PHARMACOLOGY  Mice  Mice, Inbred C57BL
       Murine Acquired Immunodeficiency Syndrome/*DRUG THERAPY/  IMMUNOLOGY
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).